Delving into the Latest Updates on Metformin Hydrochloride with Synapse

Overview

Basic Info

SummaryMetformin Hydrochloride, sold under the trade name GLUCOPHAGE, is a medication used in the treatment of type 2 diabetes mellitus. It was first approved in France in 1957 and is now manufactured by Bristol Myers Squibb Co. GLUCOPHAGE works by activating PRKAB1, which helps to improve glycemic control in both adult and pediatric patients aged 10 years and older, when used in combination with diet and exercise. This medication is a biguanide, and it is commonly used as an adjunct therapy to help manage blood sugar levels in individuals with type 2 diabetes.

Drug Type

Small molecule drug

Synonyms

Meiformin Hydrochloride, Metformin hydrochloride (JP17/USP), Metformin Hydrochlorride

+ [67]

Target

PRKAB1

Action

activators

Mechanism

PRKAB1 activators(Protein kinase AMP-activated non-catalytic subunit beta 1 activators)

Therapeutic Areas

Endocrinology and Metabolic DiseaseNeoplasmsImmune System Diseases+ [12]

Active Indication

Diabetes Mellitus, Type 2Invasive Mammary CarcinomaChronic Disease+ [49]

Inactive Indication

Acinar Cell CarcinomaAcquired Immunodeficiency SyndromeAdenocarcinoma of large intestine+ [70]

Originator Organization

Bristol Myers Squibb Co.

Active Organization

Zhengzhou University Hospital

Alliance Foundation Trials LLC

University of Texas Health Science Center At San Antonio

+ [30]

Inactive Organization

Columbia University

Turning Point Therapeutics, Inc.Merck Serono International SA

+ [24]

License Organization

Merck KGaA

The Fox Chase Cancer Center

Sylvester Comprehensive Cancer Center

+ [3]

Drug Highest PhaseApproved

First Approval Date

China (01 Jan 1992),

Diabetes Mellitus, Type 2

RegulationPriority Review (China)

Login to view timeline

Structure/Sequence

Molecular FormulaC4H12ClN5

InChIKeyOETHQSJEHLVLGH-UHFFFAOYSA-N

CAS Registry1115-70-4

Phase III, Adaptive, Multicenter, Randomized, Superiority, Double-Dummy, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor and a Thiazolidinedione in the Treatment of Type 2 Diabetes Mellitus, Compared to Monotherapy, in Patients Treated With Metformin

This clinical trial is studying whether combining two commonly used diabetes medications into a single pill works better than taking them separately for people with type 2 diabetes who are already on metformin. Both medications work in different ways to lower blood sugar - one helps remove excess sugar through urine while the other helps the body use insulin better.
The study has two main goals:
To see if the combined pill controls blood sugar more effectively than either medication alone
To check if combining them reduces common side effects like weight gain and swelling that can occur with one of the medications
Participants will be randomly assigned to one of three groups:
The new combination pill
One of the standard diabetes medications alone
The other standard diabetes medication alone
All participants will take their assigned treatment daily and attend regular clinic visits for monitoring. Doctors will track blood sugar control, weight changes, and any side effects throughout the study period.
This research could lead to a simpler treatment option that combines the benefits of both medications while potentially minimizing side effects. For people with diabetes who often need multiple medications, a combined pill might make treatment easier to manage while providing better blood sugar control.

Start Date01 Sep 2026

Sponsor / Collaborator

EUROFARMA LABORATORIOS SA

NCT07139405

/ Not yet recruitingPhase 2

A DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE II TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND SUPERIORITY OF TRIGLYTZA® OVER METFORMIN IN PATIENTS WITH INADEQUATE GLYCEMIC CONTROL OVER 24 WEEKS OF TREATMENT

Type 2 diabetes (T2DM) is still very difficult to treat because current medicines mostly help with symptoms but don't stop the damage happening inside the pancreas. Many people who start on common treatments like Metformin, and even newer drugs like Ozempic, eventually stop responding to them. This is because these drugs don't address the real problem: the gradual loss of the pancreas' ability to make insulin and the body's increasing resistance to it.
Myopharm is developing a new treatment called TriGlytza®, which combines existing medicines (Celecoxib and Valsartan) with Metformin. This new approach is designed to target the inflammation and biological pathways that cause ongoing damage in Type 2 diabetes, aiming to protect the pancreas and reduce insulin resistance. Early animal studies and past clinical trials with the individual drugs show promising results.
The number of people with Type 2 diabetes is expected to double by 2045, and the disease brings huge health and financial costs. It also raises the risk of heart disease, stroke, kidney damage, nerve problems, vision loss, certain cancers, and even conditions like Alzheimer's. Because of this, a treatment that addresses the root causes rather than just symptoms could make a major difference.
TriGlytza® aims to provide a safe, affordable, and more effective long-term treatment than current options, helping people manage their diabetes better and avoid related health problems.

Start Date01 Feb 2026

Sponsor / Collaborator

Myopharm Ltd.

NCT07136987

/ Not yet recruitingPhase 3

A Randomized Controlled Trial of 2 Disease-Modifying Drugs (Metformin and N-acetylcysteine ) to Promote TB Lung Function Recovery (TB-MET-NAC)

Tuberculosis is a leading global cause of morbidity and mortality. Even if cured, a majority patients are left with bronchiectasis and fibrosis, permanent conditions that impair lung function. Large cohort studies have confirmed that even modest loss of lung function is associated with excess mortality risk. This study will examine if two treatments, metformin and N-acetylcysteine (NAC), can promote the recovery of lung function in TB if given together with standard TB treatment. There currently are no drugs approved for this indication.

Start Date01 Jan 2026

Sponsor / Collaborator

Open Source Pharma Foundation

[+1]

100 Clinical Results associated with Metformin Hydrochloride

Login to view more data

100 Translational Medicine associated with Metformin Hydrochloride

Login to view more data

100 Patents (Medical) associated with Metformin Hydrochloride

Login to view more data

20,916

Literatures (Medical) associated with Metformin Hydrochloride

25 Dec 2025·Oriental Journal of Chemistry

Quantitative UV-Spectrophotometric Method for the Analysis of Teneligliptin HBr and Metformin HCl in Pharmaceutical Dosage form: Development and Validation

Author: Gahtori, Archana ; Khanduri, Praveen

This study developed a UV-spectrophotometric method for the simultaneous quantification of Metformin HCl and Teneligliptin HBr. Both active pharmaceutical ingredients were found to be soluble in 0.1N sulfuric acid, which was thus chosen as the solvent for analysis. The maximum absorption wavelengths for Metformin HCl and Teneligliptin HBr were identified at 220 nm and 240 nm, respectively. Standard stock solutions were prepared, and samples from commercially available tablets were accurately measured and dissolved for testing. Method validation included evaluations of linearity, precision (intra-day and inter-day), accuracy, robustness, as well as detection (LOD) and quantification limits (LOQ). The method exhibited strong precision and accuracy, with %RSD values less than 2%. Both LOD and LOQ demonstrated sufficient sensitivity, and the method proved effective for analyzing commercial formulations, achieving compliance levels of 99.20% for Metformin and 102.00% for Teneligliptin.

01 Dec 2025·IMMUNOLOGIC RESEARCH

Metformin suppresses gammadelta T17 cell differentiation alleviating DSS-induced colitis

Article

Author: Wang, Yungang ; Zhi, Yaru ; Tang, Qinfang ; Shen, Langping ; Yan, Dongmei ; Liu, Hongli ; Xiao, Lihua ; Cai, Aiting ; Sun, Mingzhong ; Ju, Huixiang ; Yang, Rui ; Chen, Hongmei

Ulcerative colitis (UC) is a chronic, nonspecific, relapsing inflammatory bowel disease. Metformin has pleiotropic effects including anti-inflammatory properties and a notable impact on the gut microbiome. γδT17 cells play crucial role in initiating and maintaining intestinal inflammation. The effect of metformin on γδT17 cells remains unclear. This study aims to explore the connection between metformin-mediated ameliorated response in colitis mice and γδT17 cell activity. The role of γδT17 cell inhibition in metformin-mediated colitis amelioration was evaluated in mice. The effect of metformin on γδT17 differentiation and the possible mechanism were evaluated in a set of in vitro experiments. Results showed that the accumulation of γδT17 cells was negatively correlated with metformin treatment in DSS-induced colitis mice. Exogenous γδT17 cells blocked metformin-mediated colitis inhibition. Furthermore, metformin inhibited γδT17 differentiation, which was related to the inhibition of mTOR/RORγt activity. Our results reveal that metformin ameliorates colitis symptoms by suppressing γδT17 differentiation, suggesting a viable strategy against UC, although the mechanism of metformin in inhibiting γδT17 differentiation remains to be further studied.

01 Dec 2025·COLLOIDS AND SURFACES B-BIOINTERFACES

Poly (lactic-co-glycolic acid) (PLGA) nanoparticles for sustained release of metformin hydrochloride within cells: A therapy for Type 2 diabetes mellitus

Article

Author: Sun, Qinyu ; Li, Jianfeng ; Song, Xinzhong ; Li, Jianyong ; Zhang, Yongqi ; Ji, Maocheng ; Man, Jia

Type 2 diabetes mellitus (T2DM) is the third leading chronic disease threatening human health, with patients primarily managing their blood glucose levels through oral administration of metformin hydrochloride (MH). However, oral delivery of the pure drug faces challenges such as low bioavailability and significant gastrointestinal side effects. To address these, we employed a high-pressure homogenizer to prepare PLGA nanoparticles encapsulating the drug via a double emulsion method. Orthogonal experiments revealed that both shear pretreatment and high-pressure homogenization significantly influenced the particle properties, which were subsequently characterized. The average particle size could reach as small as 113.00 nm, with an encapsulation efficiency up to 64.69 %. The surface of these nanoparticles was negatively charged, enabling sustained drug release for 36 h in vitro. They exhibited excellent biocompatibility, maintaining a 95.74 % cell survival rate after 48 h of co-culture with hepatocytes, and were capable of being internalized by cells. In vivo experiments demonstrated that orally administered MH-PLGA nanoparticles could sustain blood glucose lowering effects for 8-10 h. Compared with traditional oral metformin hydrochloride, MH-PLGA nanoparticles offer higher bioavailability and lower gastrointestinal side effects, which are expected to bring better therapeutic effects to patients.

392

News (Medical) associated with Metformin Hydrochloride

27 Oct 2025

·www.fiercepharma.com

Innovent, Lilly's mazdutide trumps Novo's semaglutide in head-to-head diabetes, weight loss study

Innovent signed on to license mazdutide in China through a 2019 agreement with Eli Lilly, marking an extension of a decade-long partnership between the two companies. An experimental GLP-1/glucagon (GCP) dual receptor agonist from Eli Lilly and its Chinese partner, Innovent, has bested Novo Nordisk’s reigning GLP-1 semaglutide, in a phase 3 study across both blood sugar and weight loss metrics. The late-stage trial evaluating mazdutide, the world’s first approved GLP-1/GCG, is also the first to pit a drug from the class against semaglutide in a head-to-head comparison, the Suzhou-based drugmaker said in an Oct. 26 press release.Novo markets its semaglutide as injectable Ozempic and oral Rybelsus for type 2 diabetes and as Wegovy for obesity. Innovent pitted a 6-mg dose of mazdutide against a 1-mg semaglutide regimen in its study of 349 Chinese adults with early-stage type 2 diabetes (T2D) and obesity. To qualify for the China-only trial, patients had to have inadequate glycemic and weight control after lifestyle intervention, regardless of whether they were taking standard metformin monotherapy.Mazdutide's performance against Novo's semaglutide allowed the trial to meet its primary endpoint, which looked at the proportion of patients who achieved hemoglobin A1C (HbA1C) or blood glucose levels over 7.0%, as well as body weight reduction of at least 10% from baseline at the study's 32-week mark. Some 48% of patients in the trial's mazdutide group met those blood sugar and weight loss benchmarks, compared to 21% in the semaglutide arm, Innovent said.Mazdutide also had an apparent edge over semaglutide on both blood glucose levels and weight loss separately, helping patients lower their HbA1c by 2.03% and lose 10.26% of their weight from baseline on average. Semaglutide, meanwhile, triggered a 1.84% reduction in HbA1c levels and helped patients achieve an average 6% weight loss.“Treatment strategies that address both glycemic control and weight loss are playing an increasingly critical role in improving clinical outcomes for patients with T2D and comorbid obesity,” principal trial investigator Linong Ji, M.D., explained in the release.Mazdutide, approved in China for weight management and type 2 diabetes, may benefit “a wide range of patients requiring multifaceted improvements in glycemic control, body weight, and cardiometabolic risk factors,” Innovent’s chief R&D officer of general biomedicine, Lei Qian, M.D., Ph.D., added. The drug won its first-in-class approval from China’s National Medical Products Administration (NMPA) in June, marking a breakthrough moment for incretin medicines. Targeting the GCG receptor can increase the body’s energy expenditure and improve hepatic fat metabolism, creating a powerful weight loss mechanism when added to the insulin benefits of GLP-1 agonists. Innovent signed a 2019 agreement with Lilly to license the drug in China, marking an extension of a decade-long partnership between the two companies. Lilly maintains the rights to the mazdutide outside of China, where it has yet to win approval.Mazdutide and semaglutide are also going head-to-head in another ongoing study that compares the medications in obesity accompanied metabolic-associated fatty liver disease. Innovent is planning to further study mazdutide in adolescents with obesity, metabolic dysfunction–associated steatohepatitis (MASH), certain heart failure indications and against Lilly’s tirzepatide in obesity.

Phase 3License out/inDrug ApprovalClinical Result

15 Oct 2025

·www.fiercebiotech.com

Eli Lilly\'s orforglipron bests Farxiga, padding oral GLP-1 case with pair of phase 3 diabetes wins

If everything goes to plan, Eli Lilly will file for approval of orforglipron in Type 2 diabetes in 2026.\n Eli Lilly has guided its oral GLP-1 drug candidate orforglipron through two more late-phase tests in Type 2 diabetes, racking up wins against placebo and AstraZeneca’s Farxiga to stay on track to seek approval in the indication next year.Lilly has run two sets of phase 3 trials for orforglipron, one to support approval in obesity and another to unlock the diabetes market. The company previously posted diabetes victories over placebo and oral semaglutide, Novo Nordisk’s GLP-1 drug. Wednesday, Lilly shared data from two of the remaining three trials in its diabetes program.One trial compared three doses (3 mg, 12 mg and 36 mg) of orforglipron to dapagliflozin, an SGLT-2 inhibitor that AstraZeneca sells as Farxiga. The trial enrolled adults with Type 2 diabetes inadequately controlled on metformin. At Week 40, patients\' A1C, a measure of blood glucose, fell up to 1.7% on orforglipron and 0.8% on dapagliflozin.The other trial compared the same three doses of orforglipron to placebo in adults with Type 2 diabetes and inadequate glycemic control with titrated insulin glargine. After 40 weeks of treatment, Lilly saw A1C reductions of up to 2.1% in the orforglipron arms, versus a 0.8% decline in the placebo cohort.The A1C reductions were big enough for both trials to hit their primary endpoints. Lilly said the studies also met all key secondary endpoints at 40 weeks. Patients taking orforglipron lost weight and showed improvements in multiple cardiovascular risk factors, although Lilly is yet to share the data for these endpoints. Similarly, Lilly said the safety and tolerability profile was consistent with prior studies without sharing any numbers. Lilly’s A1C data raise questions about the need for the high dose. A1C decreased 1.7% in patients taking 12 mg and 36 mg of orforglipron in the dapagliflozin comparison study. Lilly saw a larger drop in A1C on the middle, 12-mg dose than the top dose in the placebo-controlled trial. A1C fell 2.1% on the middle dose, compared to 1.9% on the top dose. Lilly plans to share more data at a future medical meeting. The topline readout means Lilly\'s drug has now delivered wins in four of the five trials in its phase 3 diabetes program. Data from the final global registration trial are due in the first quarter of next year. If everything goes to plan, Lilly will file for approval of orforglipron in Type 2 diabetes in 2026, adding to an obesity submission that is scheduled for this year.Obesity has dominated the thoughts of investors, who sent Lilly’s share price down when weight loss data fell short of expectations earlier this year. But the company sees diabetes as a big opportunity too. Patrik Jonsson, president of Lilly International, told attendees at a Wells Fargo event last month that “the oral Type 2 market in the U.S. is huge” and orforglipron could be a really good medicine in the indication.

$Eli Lilly\'s orforglipron bests Farxiga, padding oral GLP-1 case with pair of phase 3 diabetes wins$

Clinical ResultPhase 3Drug Approval

15 Oct 2025

·firstwordpharma.com

Lilly's orforglipron adds AstraZeneca's Farxiga to list of bested drugs in diabetes

Eli Lilly on Wednesday reported another success in a study pitting its once-daily oral GLP-1 therapy orforglipron against a competing type 2 diabetes therapy, this time AstraZeneca's SGLT2 inhibitor Farxiga (dapagliflozin). "Orforglipron has now demonstrated superiority over two active comparators," remarked Jeff Emmick, senior vice president of product development at Lilly Cardiometabolic Health.Last month, orforglipron beat Novo Nordisk's oral drug Rybelsus (semaglutide) on both blood glucose control and weight loss in the Phase III ACHIEVE-3 trial.The latest study, dubbed ACHIEVE-2, compared three doses of orforglipron to Farxiga in 962 participants with type 2 diabetes and inadequate glycaemic control with metformin. The trial's main goal was to demonstrate that orforglipron is non-inferior in A1C reduction from baseline after 40 weeks, compared to AstraZeneca's drug.Top-line results showed that all doses of orforglipron met the primary endpoint, as well as all key secondary goals, delivering significant A1C reduction and weight loss, as well as improvements in multiple cardiovascular risk factors. Specifically, the 3-mg dose of orforglipron led to a 1.3% reduction in A1C from baseline, rising to 1.7% for both the 12 mg and 36 mg doses, versus 0.8% for Farxiga.Lilly added that in another late-stage trial, called ACHIEVE-5, orforglipron also met its primary endpoint, as well as all key secondary goals. The study compared the same three doses of orforglipron to placebo in adults with type 2 diabetes and inadequate glycaemic control with titrated insulin glargine, with or without metformin and/or SGLT-2 inhibitors.Head-line data showed that the 3-mg dose of orforglipron led to a 1.5% reduction in A1C from baseline to week 40, while it was 2.1% for the 12-mg dose, 1.9% for the 36-mg dose and 0.8% for placebo."The findings from ACHIEVE-5 add to this momentum, showing significant A1C reduction and weight loss when used in combination with titrated basal insulin," Emmick commented.Orforglipron's overall safety and tolerability profile in the two studies, as well as treatment discontinuation rates, were consistent with previous trials, according to Lilly. The most common adverse events were gastrointestinal-related and generally mild-to-moderate in severity, while no hepatic safety signal was observed (for related analysis, see Spotlight On: Lilly brushes aside orforglipron safety scare).Detailed findings from the studies will be presented at a future medical meeting. Results from ACHIEVE-4, the final global registration trial in the ACHIEVE programme, are anticipated in the first quarter of 2026, teeing up marketing applications for orforglipron in type 2 diabetes.Meanwhile, orforglipron submissions for the treatment of obesity are on track to occur by the end of this year. The therapy was discovered by Chugai Pharmaceutical and licensed by Lilly in 2018.

Clinical ResultPhase 3

100 Deals associated with Metformin Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00944	Metformin Hydrochloride	A10BA02	DBSALT000114

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus	United States	Andrx Labs LLC	27 Apr 2004
Diabetes Mellitus, Type 2	China	Ankang Zhengda Pharmaceutical Co. Ltd.	01 Jan 1992

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Invasive Mammary Carcinoma	Phase 3	United States	City of Hope National Medical Center	16 Dec 2024
Chronic Disease	Phase 3	United States	Oklahoma Medical Research Foundation	29 Jul 2020
Acquired Immunodeficiency Syndrome	Phase 3	United States	Merck Sharp & Dohme Corp.	01 Feb 2019
Aortic Aneurysm, Abdominal	Phase 3	Austria	Merck Serono GmbH	26 Sep 2018
Fragile X Syndrome	Phase 3	United States	University of California, Davis	30 Apr 2018
Fragile X Syndrome	Phase 3	Canada	University of California, Davis	30 Apr 2018
Metabolic Syndrome	Phase 3	United States	Rutgers State University of New Jersey	07 Aug 2017
Atypical hyperplasia	Phase 3	United States	Alliance Foundation Trials LLC	23 Nov 2015
Breast Cancer	Phase 3	United States	Alliance Foundation Trials LLC	23 Nov 2015
Breast hyperplasia	Phase 3	United States	Alliance Foundation Trials LLC	23 Nov 2015

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03355469 (CTgov)	Phase 2/3	Metabolic Syndrome	91	Placebo (LoEx With Placebo)	jbtgqiurua(qzldgcmerh) = tcqxxssofg eogmjwofvz (ognsyxzlao, qxlymwqahu - qsarjsjlfr) View more	-	22 Sep 2025
				High Intensity Exercise (HiEx With Placebo)	jbtgqiurua(qzldgcmerh) = oakqeziyij eogmjwofvz (ognsyxzlao, rdyenszqkr - eqzukdyxxf) View more
NCT03765359 (Pubmed \| Diabetes Metab Res Rev)	Phase 4	Diabetes Mellitus, Type 1	101	Metformin (Type 1 Diabetes)	slgxxllrau(mektcgpetg): P-Value = 0.193 View more	Positive	01 Sep 2025
				Placebo (Type 1 Diabetes)
NCT02570672 (CTgov)	Phase 2	Frailty Syndrome	141	metformin (Metformin)	njfsmnsdzc(hkzidfvfoj) = rbevjmnwzr azfbiizfkp (djjzkvvqnv, 0.0002) View more	-	06 Aug 2025
				Placebo (Placebo)	njfsmnsdzc(hkzidfvfoj) = qjnwqfihnl azfbiizfkp (djjzkvvqnv, 0.0002) View more
NCT00268476 (STAMPEDE, Pubmed \| Lancet Oncol)	Phase 3	Metastatic Prostate Carcinoma	1,874	Metformin (Standard of care)	dqdsniesul(qiesdluldy) = The side-effect profile of metformin was as expected and consisted mainly of diarrhoea vwlycimfia (ynvcxfikmq )	Negative	01 Aug 2025
				Standard of care + Metformin 850 mg twice daily
NCT06042855 (CTgov)	Phase 3	COVID-19	3,214	Metformin (Arm G - Metformin)	brsavlxccr(omjlsrmbfr) = vecvoeuqhn frzqawgdpe (jwyxbidewk, atxqcjhkig - dcgeltwvss) View more	-	20 Jul 2025
				Placebo (Arm G - Placebo)	brsavlxccr(omjlsrmbfr) = yehkxqaobf frzqawgdpe (jwyxbidewk, mimbkpcpyz - crfrhjkjbn) View more
Pubmed \| JAMA Intern Med	Phase 3	COVID-19	2,991	Metformin	kxtflcfjya(bvxnggvyei) = juiytrdetn kaxtvtydnv (vowcyybpml )	Negative	14 Jul 2025
				Placebo	kxtflcfjya(bvxnggvyei) = cshbdtrpdb kaxtvtydnv (vowcyybpml )
NCT05288153 (Pubmed \| Chin Med J (Engl))	Phase 4	Gastritis, Hypertrophic Helicobacter pylori tests	140	Metformin 500 mg daily	hnfkfwriqm(tpsiwaphgl) = kztthgquxn abdnhbnlhi (ncyreznbpq, 34/70)	Positive	16 Jun 2025
				Folate 5 mg three times daily	hnfkfwriqm(tpsiwaphgl) = wxbtmsowwi abdnhbnlhi (ncyreznbpq, 22/70)
NCT01697566 (CTgov)	Phase 3	Endometrial Carcinoma \| Hyperinsulinism	29	Metformin (Metformin + Lifestyle)	rgyfuriign(fluffmvcym) = ikwtokunlz xcrndaphng (pifvqpllct, 22.51) View more	-	11 Jun 2025
				Metformin (Metformin + No Lifestyle)	rgyfuriign(fluffmvcym) = yluaxymtvx xcrndaphng (pifvqpllct, 15.36) View more
JPRN-jRCTs031200326 (Phase I/II study of maintenance therapy with metformin and temozolomide for newly diagnosed glioblastoma, ASCO2025)	Phase 1/2	Glioblastoma Maintenance	22	Metformin	ayelewticj(dhusurbwfl) = qozabbpftx rqzgiebbzy (stlqstemma, 29.2 - 64.0)	Positive	30 May 2025
				Temozolomide	pcqwxnovwf(epsxioqmhy) = llcnzuryyk eqpxywxpdr (wmxjbtdooj )
NCT01905046 (CTgov)	Phase 3	Breast hyperplasia \| Breast Cancer \| Noninfiltrating Intraductal Carcinoma ... View more	86	metformin hydrochloride (Arm I)	zpskwitxnh: Odds Ratio (OR) = 0.97 (95% CI, 0.36 - 2.62), P-Value = 0.951	-	13 Apr 2025
				placebo+Metformin (Arm II)